Icotrokinra: "1° endpoint: Clinical response = 63.5%"; Ulcerative colitis (Protagonist Therapeutics) - Nov 5, 2025 - Corporate Presentation: "2° endpoint: Clinical remission =
30.2%"
P2b data • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis
|